Jiangxi Bio (06915) has announced that the price stabilization period related to its global offering concluded on July 25, 2026, which is the 30th day after the deadline for submitting Hong Kong public offering applications.

The overall coordinator did not exercise the over-allotment option during the stabilization period, and the option has lapsed as of July 25, 2026. Consequently, no H-shares will be issued under the over-allotment option.

China International Capital Corporation Hong Kong Securities Limited, acting as the stabilization agent, or its affiliates or any person acting on their behalf, took the following stabilization actions during the period: an over-allotment of 5.435 million H-shares in the international offering; and continuous market purchases of a total of 5.435 million H-shares at prices ranging from HKD 7.40 to HKD 10.46 per share, to deliver to subscribers who have agreed to delayed delivery of the relevant H-shares subscribed under the global offering.